Patents Assigned to Shire Laboratories, Inc.
  • Publication number: 20060210625
    Abstract: An oral pharmaceutical composition, comprising one or more positively charged, highly water-soluble pharmaceutically active agents such as trospium chloride, and one or more polymers containing polarized oxygen atoms, whereby the active agent(s) form an ion-dipole interaction with the polymer(s) that may be used for an immediate release system, an extended release system or a delayed release system.
    Type: Application
    Filed: November 4, 2004
    Publication date: September 21, 2006
    Applicant: Shire Laboratories, Inc.
    Inventor: Argaw Kidane
  • Patent number: 7022337
    Abstract: A fibrate self-emulsifying oral formulation with improved bioavailability when compared to commercially available formulations containing a therapeutically effective dose of fenofibrate, derivative of fenofibrate or mixtures thereof dissolved in a fibrate solubilizer selected from N-alkyl derivative of 2-pyrrolidone, mono- or di- or polyethylene glycol monoethers, C8-12 fatty acid mono- or di-esters of propylene glycol, or combinations thereof, one or more surfactants and optionally one or more stabilizers useful in the treatment of hypercholesterolaemia or hypertriglyceridaemia in mammals in the fed or fasted state.
    Type: Grant
    Filed: June 27, 2003
    Date of Patent: April 4, 2006
    Assignee: Shire Laboratories, Inc.
    Inventors: Likan Liang, Amir H. Shojaei, Scott A. Ibrahim, Beth A. Burnside
  • Patent number: 7011846
    Abstract: A formulation for a stabilized capsule for oral administration of a hydrophobic pharmaceutically active agent; comprising a non-aqueous solubilizer selected from 2-pyrrolidone, N-alkylpyrrolidones and combinations thereof; and a capsule stabilizing agent selected from mono-, di- and triglycerides, mono- and di-fatty esters of polyethylene glycol, fatty acids and combinations thereof wherein capsule integrity is maintained for at least 24 hours is disclosed.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: March 14, 2006
    Assignee: Shire Laboratories, Inc.
    Inventors: Amir H. Shojaei, Scott A. Ibrahim, Beth A. Burnside
  • Publication number: 20050191343
    Abstract: The present invention is directed to reverse micellar formulations for the delivery of hydrophobic or lipophilic compounds, particularly therapeutic compounds.
    Type: Application
    Filed: November 24, 2004
    Publication date: September 1, 2005
    Applicant: Shire Laboratories, Inc.
    Inventor: Likan Liang
  • Publication number: 20050191351
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: November 4, 2004
    Publication date: September 1, 2005
    Applicant: Shire Laboratories, Inc.
    Inventors: Argaw Kidane, Henry Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Patent number: 6913768
    Abstract: A pharmaceutical composition comprises a once-a-day sustained release formulation of at least one amphetamine salt which provides mean plasma concentration profile aspects in human ADHD patients which are substantially the same as that provided by ADDERALL XR® type pulsatile formulations.
    Type: Grant
    Filed: January 29, 2003
    Date of Patent: July 5, 2005
    Assignee: Shire Laboratories, Inc.
    Inventors: Richard A. Couch, Beth A. Burnside, Rong-Kun Chang
  • Publication number: 20050123606
    Abstract: An oral pharmaceutical dosage form with enhanced gastrointestinal permeability, comprising a therapeutic quaternary ammonium compound together with an organic acid.
    Type: Application
    Filed: November 4, 2004
    Publication date: June 9, 2005
    Applicant: Shire Laboratories, Inc.
    Inventor: Argaw Kidane
  • Patent number: 6890918
    Abstract: A pharmaceutical composition comprising an inhibitor of angiotensin converting enzyme and neutral endopeptidase, such as sampatrilat, and at least one bioavailability enhancer such as an organic acid, e.g., ascorbic acid. Such a composition has improved systemic bioavailability.
    Type: Grant
    Filed: April 30, 2002
    Date of Patent: May 10, 2005
    Assignee: Shire Laboratories, Inc.
    Inventors: Beth Burnside, Rong-Kun Chang, Amir Shojaei
  • Patent number: 6838093
    Abstract: An osmotic system for delivering a pharmaceutically active agent which comprises a core portion, a layer portion enclosing the core portion, and a semipermeable wall portion enclosing the core portion and the layer portion. The core portion includes the pharmaceutically active agent at a first concentration. The pharmaceutically active agent is present in the layer portion at a second concentration. The second concentration is greater than the first concentration. Such a system provides for the osmotic release of the pharmaceutically active agent in release profile other than a zero order release profile, and wherein the release profile is similar to or approaches or reaches a first order release profile.
    Type: Grant
    Filed: June 1, 2001
    Date of Patent: January 4, 2005
    Assignee: Shire Laboratories, Inc.
    Inventors: Henry H. Flanner, Lisa C. McKnight, Beth A. Burnside
  • Patent number: 6814979
    Abstract: Disclosed is an osmotic pharmaceutical delivery system comprising (a) a semi-permeable wall that maintains its integrity during pharmaceutical delivery and which has at least one passage therethrough; (b) a single, homogeneous composition within said wall, which composition consists essentially of (i) a pharmaceutically active agent, (ii) at least one non-swelling solubilizing agent which enhances the solubility of the pharmaceutically active agent; (iii) at least one non-swelling osmotic agent and (iv) a non-swelling wicking agent dispersed throughout the composition which enhances the surface area contact of the pharmaceutical agent with the incoming aqueous fluid.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: November 9, 2004
    Assignee: Shire Laboratories, Inc.
    Inventors: Edward M. Rudnic, Beth A. Burnside, Henry H. Flanner, Sandra E. Wassink, Richard A. Couch, Jill E. Pinkett
  • Patent number: 6811794
    Abstract: A pharmaceutical composition comprising at least one pharmaceutically active agent that is pH dependent, at least one non-pH dependent sustained release agent, and at least one pH dependent agent that increases the dissolution rate of the at least one pharmaceutically active agent at a pH in excess of 5.5. Such compositions have minimized pH-dependent dissolution profiles or pH-independent dissolution profiles.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: November 2, 2004
    Assignee: Shire Laboratories, Inc.
    Inventors: Beth A. Burnside, Rong-Kun Chang, Xiaodi Guo
  • Patent number: 6793934
    Abstract: A pharmaceutical composition comprising a solid carrier containing a liquid selected from the group consisting of a liquid active agent, a liquid enhancer, or a combination thereof.
    Type: Grant
    Filed: December 8, 1999
    Date of Patent: September 21, 2004
    Assignee: Shire Laboratories, Inc.
    Inventors: Beth A. Burnside, Henry Flanner, Xiaodi Guo, Rong Kun Chang
  • Patent number: 6772801
    Abstract: Encapsulated oral dosage pharmaceutical products are produced utilizing a system including a hopper and a dosator, where the hopper receives particles having irregular geometries and sizes greater than about 100 &mgr;m for delivery to the dosator. A gaseous fluid is directed into the hopper to fluidize particles within the hopper so as to minimize or eliminate the formation of voids within the bed of particles disposed within the hopper. The fluidization of the particles within the hopper maintains a substantially continuous and uniform flow of particles from the hopper to the dosator, which results in the formation of encapsulated products with desirable weights and particle size distributions.
    Type: Grant
    Filed: May 14, 2003
    Date of Patent: August 10, 2004
    Assignee: Shire Laboratories, Inc.
    Inventors: Amir H. Shojaei, Benjamin Thomas Kibalo, Scott A. Ibrahim
  • Publication number: 20040059002
    Abstract: A pharmaceutical composition comprises a once-a-day sustained release formulation of at least one amphetamine salt which provides mean plasma concentration profile aspects in human ADHD patients which are substantially the same as that provided by ADDERALL XR® type pulsatile formulations.
    Type: Application
    Filed: January 29, 2003
    Publication date: March 25, 2004
    Applicant: SHIRE LABORATORIES, INC.
    Inventors: Richard A. Couch, Beth Burnside, Rong-Kun Chang
  • Patent number: 6692767
    Abstract: Disclosed is a beadlet comprising (i) a hydrophobic long chain fatty acid or ester material; (ii) a surfactant; and (iii) a therapeutic agent which in admixture form a solid solution at room temperature. The hydrophobic material preferably has a melting point of about 40 to about 100° C., and is most preferably glyceryl behenate. The surfactant is preferably a polyglycolyzed glyceride, polyoxyethylene sorbate, ethylene or propylene block copolymer or combinations thereof, and is most preferably polyoxyethylene 20 sorbitan monolaurate.
    Type: Grant
    Filed: September 18, 1998
    Date of Patent: February 17, 2004
    Assignee: Shire Laboratories Inc.
    Inventors: Beth A. Burnside, Charlotte M. McGuinness, Edward M. Rudnic, Richard A. Couch, Xiaodi Guo, Alexander K. Tustian
  • Patent number: 6605300
    Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.
    Type: Grant
    Filed: July 19, 2001
    Date of Patent: August 12, 2003
    Assignee: Shire Laboratories, Inc.
    Inventors: Beth A. Burnside, Xiaodi Guo, Kimberly Fiske, Richard A. Couch, Donald J. Treacy, Rong-Kun Chang, Charlotte M. McGuinness, Edward M. Rudnic
  • Patent number: 6514532
    Abstract: Disclosed is an osmotic pharmaceutical delivery system comprising (a) a semi-permeable wall that maintains its integrity during pharmaceutical delivery and which has at least one passage therethrough; b) a single, homogeneous composition within said wall, which composition consists essentially of (i) a pharmaceutically active agent, (ii) at least one non-swelling solubilizing agent which enhances the solubility of the pharmaceutically active agent; (iii) at least one non-swelling osmotic agent and (iv) a non-swelling wicking agent dispersed throughout the composition which enhances the surface area contact of the pharmaceutical agent with the incoming aqueous fluid.
    Type: Grant
    Filed: December 28, 2001
    Date of Patent: February 4, 2003
    Assignee: Shire Laboratories, Inc.
    Inventors: Edward M. Rudnic, Beth A. Burnside, Henry H. Flanner, Sandra E. Wassink, Richard A. Couch, Jill E. Pinkett
  • Publication number: 20020102306
    Abstract: Disclosed is an osmotic pharmaceutical delivery system comprising (a) a semi-permeable wall that maintains its integrity during pharmaceutical delivery and which has at least one passage therethrough; b) a single, homogeneous composition within said wall, which composition consists essentially of (i) a pharmaceutically active agent, (ii) at least one non-swelling solubilizing agent which enhances the solubility of the pharmaceutically active agent; (iii) at least one non-swelling osmotic agent and (iv) a non-swelling wicking agent dispersed throughout the composition which enhances the surface area contact of the pharmaceutical agent with the incoming aqueous fluid.
    Type: Application
    Filed: December 28, 2001
    Publication date: August 1, 2002
    Applicant: Shire Laboratories, Inc.
    Inventors: Edward M. Rudnic, Beth A. Burnside, Henry H. Flanner, Sandra E. Wassink, Richard A. Couch
  • Patent number: 6384020
    Abstract: A pharmaceutical composition comprising lactitol and one or more amphetamine salts in a rapid release formulation.
    Type: Grant
    Filed: July 6, 2000
    Date of Patent: May 7, 2002
    Assignee: Shire Laboratories, Inc.
    Inventors: Henry H. Flanner, Rong-Kun Chang, Jill E. Pinkett, Sandra E. Wassink, Lisa R. White
  • Patent number: RE41148
    Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.
    Type: Grant
    Filed: October 20, 1999
    Date of Patent: February 23, 2010
    Assignee: Shire Laboratories, Inc.
    Inventors: Beth A. Burnside, Xiaodi Guo, Kimberly Fiske, Richard A. Couch, Donald J. Treacy, Rong-Kun Chang, Edward M. Rudnic, Charlotte M. McGuinness